Physician profile
Catherine Lowe
NPI 1437175643
$7,798.44
in general payments reported to CMS, 2019-2025
29 companies · $353 in 2025
The $353 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,765 · 2020: $182 · 2021: $1,553 · 2022: $1,353 · 2023: $1,472 · 2024: $1,119 · 2025: $353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,944.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,944.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $710.18 | 2019-2022 | |
| Horizon Therapeutics Plc | $691.49 | 2021-2023 | Tepezza |
| Allergan, INC. | $632.96 | 2019-2022 | |
| Genentech USA, INC. | $491.63 | 2022-2025 | Vabysmo, Susvimo |
| Kala Pharmaceuticals, INC. | $362.73 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $358.60 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $345.87 | 2019-2020 | |
| Carl Zeiss Meditec USA, INC. | $340.11 | 2023-2025 | Quatera 700 |
| Rayner Intraocular Lenses Limited | $338.24 | 2022-2024 | Rayone Spheric, Omidria, Rayone Aspheric |
| Harrow Eye, LLC | $319.73 | 2024 | Iheezo |
| Mallinckrodt Hospital Products INC. | $318.10 | 2021-2024 | Acthar |
| Bausch & Lomb Americas INC. | $290.46 | 2022-2024 | Vyzulta, Miebo, Prolensa |
| Alcon Vision LLC | $260.11 | 2021-2023 | Clareon |
| Biotissue Holdings INC. | $254.82 | 2021-2022 | |
| Abbvie INC. | $249.99 | 2022-2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $247.49 | 2021-2023 | Tecnis Iol |
| Eyevance Pharmaceuticals LLC | $238.10 | 2019-2022 | |
| Sight Sciences, INC. | $137.37 | 2019-2023 | Tearcare System |
| New World Medical,INC. | $127.42 | 2024 | Kahook Dual Blade, Ahmed Glaucoma Valve, Streamline |
| Dutch Ophthalmic, USA | $125.00 | 2023 | Eva, Combined Machine, Tissueblue |
| Mallinckrodt Enterprises LLC | $122.51 | 2019 | |
| Ocular Therapeutix, INC. | $120.71 | 2023 | Dextenza |
| Ani Pharmaceuticals, INC. | $120.65 | 2024 | Purified Cortrophin Gel |
| Regeneron Healthcare Solutions, INC. | $118.75 | 2023 | Eylea |
| Spark Therapeutics, INC. | $105.68 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $105.33 | 2024 | Xdemvy |
| Dompe US, INC. | $102.57 | 2021 | |
| Oyster Point Pharma, INC. | $97.57 | 2022 | |
| Amgen INC. | $64.27 | 2025 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Lowe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.